Provided by Tiger Trade Technology Pte. Ltd.

KALA BIO

0.1757
-0.0243-12.15%
Post-market: 0.1740-0.0017-0.97%19:58 EDT
Volume:4.47M
Turnover:822.04K
Market Cap:160.06M
PE:-0.03
High:0.2041
Open:0.2041
Low:0.1607
Close:0.2000
52wk High:20.60
52wk Low:0.1607
Shares:911.00M
Float Shares:911.00M
Volume Ratio:1.47
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8254
EPS(LYR):-10.1450
ROE:-708.34%
ROA:-65.81%
PB:-18.47
PE(LYR):-0.02

Loading ...

Kala Bio Settles $10.6 Million Debt with Oxford Finance

Reuters
·
Jan 06

KALA BIO Settles Approximately $10.6 Million of Debt

THOMSON REUTERS
·
Jan 06

KALA BIO Inc - Pays $2 Mln to Oxford Finance Llc as Part of Settlement Agreement, Settles All Obligations - SEC Filing

THOMSON REUTERS
·
Jan 03

Kala Bio Inc. Settles $10.6 Million Debt with $2 Million Payment to Oxford Finance

Reuters
·
Jan 03

Kala Bio Inc. Announces Date for 2025 Annual Meeting of Stockholders

Reuters
·
Dec 31, 2025

Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading?

Benzinga_recent_news
·
Dec 24, 2025

KALA BIO Raises $10 Million From Direct Offering

MT Newswires Live
·
Dec 06, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:45 AM

Reuters
·
Dec 04, 2025

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Dec 04, 2025

KALA BIO Inc - Purchase Price Set at $1.00 per Share in Direct Offering

THOMSON REUTERS
·
Dec 04, 2025

Press Release: KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Dow Jones
·
Dec 04, 2025

Why Did KALA BIO Shares Jump Over 22% After Hours?

Benzinga_recent_news
·
Dec 04, 2025

Kala Bio Inc. Files Initial Beneficial Ownership Statement Naming Oxford Finance LLC

Reuters
·
Dec 04, 2025

Top Midday Gainers

MT Newswires Live
·
Dec 02, 2025

KALA BIO Inc: Continuing to Evaluate and Redevelop Co's Product Candidates While Actively Exploring Strategic Opportunities

THOMSON REUTERS
·
Dec 01, 2025

KALA BIO Inc - David E. Lazar Appointed as Kala's CEO and Chairman

THOMSON REUTERS
·
Dec 01, 2025

KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

GlobeNewswire
·
Dec 01, 2025

Kala Bio Inc. Files Initial Statement of Beneficial Ownership for CEO and Director David E. Lazar

Reuters
·
Nov 27, 2025

What Sparked KALA BIO's Nearly 38% Surge Overnight?

Benzinga
·
Nov 26, 2025

BRIEF-Kala Bio Inc - On Nov 21, Board Terminated Without Cause The Employment Of Mary Reumuth, Company's Chief Financial Officer

Reuters
·
Nov 26, 2025